Tandem Diabetes Care, Inc.
HealthcareNASDAQ:TNDM · NASDAQ Global Market
+$0.80 today
Vol 1.75M · Avg 2.36M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$204.7M -113.2% | -$96.0M +56.9% | -$222.6M -135.3% | -$94.6M -707.7% | $15.6M | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $13.8M -16.7% | $16.6M +5.7% | $15.7M +9.7% | $14.3M +3.5% | $13.8M | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $92.4M -8.9% | $101.4M +15.1% | $88.1M +3.7% | $84.9M +39.8% | $60.8M | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$23.0M -95.6% | -$11.8M +33.4% | -$17.7M -280.4% | -$4.6M -132.3% | $14.4M | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | -$56.8M -173.2% | -$20.8M -586.2% | $4.3M +154.6% | -$7.8M +74.7% | -$31.0M | $592.6M | $1.3B | $626.2M |
| Inventory | $24.8M +327.1% | $5.8M +112.6% | -$46.1M -8.5% | -$42.5M -756.9% | -$5.0M | $1.0B | $1.2B | $1.1B |
| Accounts Payables | $2.2M +193.1% | -$2.4M +50.8% | -$4.9M -119.9% | $24.5M +138.4% | $10.3M | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | $6.7M +20.3% | $5.6M -80.7% | $29.0M +37.0% | $21.1M -47.2% | $40.0M | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $111.8M +696.3% | $14.0M -86.6% | $104.7M +107.5% | $50.5M +639.4% | $6.8M | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$9.7M -140.1% | $24.2M +176.2% | -$31.8M -163.0% | $50.5M -54.7% | $111.4M | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$19.9M -3.7% | -$19.2M +28.3% | -$26.8M +21.4% | -$34.1M -45.0% | -$23.5M | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | $0 | $0 +100.0% | -$69.5M -170.2% | -$25.7M | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | -$85.7M +67.6% | -$264.3M +50.7% | -$535.7M -14.5% | -$467.7M +36.2% | -$733.4M | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $257.1M -16.1% | $306.5M -43.9% | $546.2M -4.1% | $569.5M -0.1% | $570.0M | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$78.6M -69.4% | -$46.4M | $0 +100.0% | -$8.9M +5.1% | -$9.3M | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | $72.9M +410.3% | -$23.5M +72.6% | -$85.7M -358.5% | $33.2M +117.7% | -$186.9M | $4.8B | $6.4B | $5.1B |
| Debt Repayment | -$40.8M -190.8% | $44.9M | $0 | $0 | $0 | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | -$2.6M +61.3% | -$6.7M | $0 -100.0% | $17.6M | $0 | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | $0 +100.0% | -$30.0M | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $0 -100.0% | $183.0K -95.6% | $4.1M +709.3% | -$675.0K -101.3% | $51.9M | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | -$43.4M -618.3% | $8.4M +103.4% | $4.1M -75.6% | $16.9M -67.5% | $51.9M | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $1.6M +28.3% | $1.3M +692.5% | -$212.0K -125.6% | $827.0K +440.5% | $153.0K | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $21.4M +106.4% | $10.4M +109.1% | -$113.6M -212.2% | $101.3M +532.5% | -$23.4M | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$29.7M -694.1% | $5.0M +108.5% | -$58.6M -458.1% | $16.4M -81.4% | $87.8M | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.59B
Kodiak Sciences Inc.
NASDAQ:KOD
$1.80B
Septerna, Inc.
NASDAQ:SEPN
$1.62B
Fortrea Holdings Inc.
NASDAQ:FTRE
$1.56B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.47B
UroGen Pharma Ltd.
NASDAQ:URGN
$1.45B
Integra LifeSciences Holdings Corporation
NASDAQ:IART
$1.38B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.09B
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
$827.07M
InMode Ltd.
NASDAQ:INMD
$817.88M
SEC Filings
Recent regulatory filings
No filings found.
Does TNDM generate free cash flow?
Tandem Diabetes Care, Inc. (TNDM) generated -$29,669,000.00 of free cash flow in fiscal 2025.
How much operating cash flow does TNDM produce?
Operating cash flow was -$9,721,000.00, before capital expenditures of $19.95M.
Explore More
Continue the stock analysis
Jump to another research area for this company.